Inter Partes Review

Abatacept (Orencia)

U.S. Patent 8,476,239
Patent Owner: Bristol-Myers Squibb
Title: Stable Protein Formulations

Adalimumab (Humira)

U.S. Patent 8,889,135
Patent Owner: Abbvie Biotechnology, Ltd.
Title: Methods of Administering anti-TNFa-antibodies

U.S. Patent 9,017,680
Patent Owner: Abbvie Biotechnology, Ltd.
Title: Methods of Administering anti-TNFa antibodies

U.S. Patent 9,073,987
Patent Owner: AbbVie Biotechnology, Ltd.
Title: Methods of Administering anti-TNFa antibodies

U.S. Patent 9,085,619
Patent Owner:  Abbvie Biotechnology
Title: Anti-TNF Antibody Formulations

U.S. Patent 8,802,100
Patent Owner:  AbbVie  Biotechnology
Title:  Formulation of human antibodies for treating TNF-alpha associated disorders

U.S. Patent 9,512,216
Patent Owner:  AbbVie Biotechnology
Title:  Use of TNFa Inhibitor

  • IPR2017-01824, filed by Sandoz
  • IPR2018-00002, filed by Sandoz
    • Filing date: October 2, 2017
    • Status: Institution decision pending as October 2, 2017.

U.S. Patent 8,911,737
Patent Owner:  AbbVie Biotechnology
Title:  Methods of administering anti-TNFa antibodies

U.S. Patent 9,090,689
Patent Owner:  AbbVie Biotechnology
Title:  Use of TNFa inhibitor for treatment of psoriasis

U.S. Patent 9,067,992
Patent Owner:  AbbVie Biotechnology
Title:  Use of TNFa inhibitor for treatment of psoriatic arthritis

U.S. Patent 8,916,157
Patent Owner:  AbbVie Biotechnology
Title:  Formulation of human antibodies for treating TNF-a associated disorders

U.S. Patent 8,916,158
Patent Owner: AbbVie Biotechnology
Title: Formulation of Human Antibodies for Treating RNF-a Associated Disorders

U.S. Patent 9,114,166
Patent Owner: AbbVie Biotechnology
Title:  Formulation of Human Antibodies for Treating TNF-a Associated Disorders

U.S. Patent 9,187,559
Patent Owner: Abbvie Biotechnology
Title:  Multiple-Variable Dose Regimen for Treating Idiopathic Inflammatory Bowel Disease

  • IPR2018-00156, filed by Sandoz
    • Filing date: November 6, 2017
    • Status: Institution decision pending as of Nov. 6, 2017

Bevacizumab (Avastin)

U.S. Patent 7,622,115
Patent Owner:  Genentech
Title: Treatment with anti-VEGF antibodies

U.S. Patent 9,795,672
Patent Owner: Genentech
Title: Treatment with Anti-VEGF Antibodies

  • IPR2018-00373, filed by Pfizer
    • Filing date: January 5, 2018
    • Status: Institution pending as of January 5, 2018.

Dipolumab (Dupixent)

U.S. Patent 8,679,487
Patent Owner: Immunex Corp.
Title: Anti-interleukin-4 receptor antibodies

Etanercept (Enbrel)

U.S. Patent 8,163,522
Patent Owner:  Hoffman-Laroche
Title:  Human TNF receptor

U.S. Patent 8,063,186
Patent Owner: Genentech
Title: Antibodies to PRO7436 polypeptides

Insulin Glargine (Lantus)

U.S. Patent 7,476,652
Patent Owner: Sanofi
Title:  Acidic Insulin Preparations having Improved Stability

Natalizumab (Tysabri)

U.S. Patent 8,815,236
Patent Owner: Biogen
Title:  Method for Treating Multiple Sclerosis and Crohn’s Disease

U.S. Patent 8,349,321
Patent Owner: Biogen
Title:  Immunoglobin Formulation and Method of Preparation Thereof

U.S. Patent 8,900,577
Patent Owner: Biogen
Title: Immunoglobulin Formulation and Method of Preparation thereof

Pegfilgrastim  (Neulasta)

U.S. Patent 8,952,138
Patent Owner:  Amgen
Title:  Refolding proteins using a chemically controlled redox state

Rituximab (Rituxan)

U.S. Patent 7,820,161
Patent Owner: Biogen
Title: Treatment of Autoimmune Diseases

  • IPR2016-01614, filed by Celltrion
  • IPR2017-01115, filed by Pfizer
  • IPR2015-00415, filed by Boehringer Ingelheim
  • IPR2015-01744, filed by Celltrion
    • Filing date: August 17, 2015
    • Status: Terminated prior institution following motion to dismiss by petitioner on October 6, 2015.

U.S. Patent 7,976,838
Patent Owner: Genentech
Title: Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNFa inhibitor

U.S. Patent 8,329,172
Patent Owner:  Biogen
Title:  Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody

U.S. Patent 8,557,244
Patent Owner: Biogen
Title:  Treatment of Aggressive Non-Hodgkins Lymphoma with Anti-CD20 Antibody

U.S. Patent 9,296,821
Patent Owner: Biogen
Title: Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibodies

U.S. Patent 7,682,612
Patent Owner:  Genentech
Title:  Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody

U.S. Patent 8,206,711
Patent Owner: Genentech
Title: Treatment of Chronic Lymphocytic Leukemia Using Anti-CD20 Antibodies

U.S. Patent 8,821,873
Patent Owner: Biogen
Title: Treatment of Diffuse Large-cell Lymphoma with Anti-CD20 Antibody

U.S. Patent 8,545,843
Patent Owner: Biogen
Title: Treatment of Vasculitis

  • IPR2018-00086, Petitioner: Pfizer
    • Filing Date: November 2, 2017
    • Status: Institution decision pending as of November 2, 2017

U.S. Patent 9,504,744
Patent Owner: Biogen
Title: Treatment of Diffuse Large-Cell Lymphoma with Anti-CD20 Antibody

  • IPR2018-00231, filed by Pfizer
    • Filing date: December 1, 2017
    • Status:  Institution pending as of December 1, 2017

Trastuzumab (Herceptin)

U.S. Patent 6,407,213
Patent Owner: Genentech
Title: Methods for Making humanized antibodies

U.S. Patent 7,846,441
Patent Owner:  Genentech
Title:  Treatment with Anti-ErbB2 Antibodies

  • IPR2018-00016, filed by Pfizer
    • Filing date: October 3, 2017
    • Status: Institution decision pending as of October 3, 2017.
  • IPR2017-02063, filed by Pfizer
  • IPR2018-00192, filed by Samsung Bioepis
    • Filing date: November 30, 2017
    • Status: Institution pending as of November 30, 2017

U.S. Patent 7,892,549
Patent Owner: Genentech
Title:  Treatment with Anti-ErbB2 Antibodies

  • IPR2017-01960, filed by Samsung Bioepis

U.S. Patent 6,627,196
Patent Owner: Genentech
Title:  Dosages for Treatment with Anti-ErbB2 Antibodies

  • IPR2017-01958, filed by Samsung Bioepis

U.S. Patent 7,371,379
Patent Owner: Genentech
Title:  Dosages for Treatment with  Anti-ErbB2 Antibodies

  • IPR2017-01959, filed by Samsung Bioepis

U.S. Patent 8,591,897
Patent Owner: Genentech
Title:  Anti-ErbB2 Antibody Adjuvant Therapy

  • IPR2017-01726, filed by Pfizer
    • Filing date: June 30, 2017
    • Status: Institution decision pending as of June 30, 2017.
  • IPR2017-01727, filed by Pfizer
    • Filing date: June 30, 2017
    • Status: Institution decision pending as of June 30, 2017.
  • IPR2017-00959, filed by Celltrion
    • Filing date: February 21, 2017
    • Status: Terminated following Patent Owner request for adverse judgment on September 11, 2017.

U.S. Patent 6,339,142
Patent Owner: Genentech
Title: Protein Purification

  • IPR2017-02019, filed by Pfizer
  • IPR2018-00330, filed by Pfizer
    • Filing date: Dec. 18, 2017
    • Status: Institution pending as of Dec. 18, 2017; Motion for joinder with Pfizer’s IPR2017-02019 filed on December 22, 2017.

U.S. Patent 9,249,218
Patent Owner:  Genentech
Title: Protein Purification

  • IPR2017-02020, filed by Pfizer
  • IPR2018-00331, filed by Pfizer
    • Filing date: Dec. 19, 2017
    • Status: Institution decision pending as of Dec. 18, 2017; Motion for joinder with Pfizer’s IPR2017-02020 filed on December 22, 2017.

General Biologic Patents

U.S. Patent 6,716,602
Patent Owner: Genentech
Title:  Metabolic Rate Shifts in Fermentations Expressing Recombinant Proteins

U.S. Patent 9,051,556
Patent Owner: Shire
Title: Purification of iduronate-2-sulfatase

U.S. Patent 6,946,292
Patent Owner: Kyowa Kakko Kirin Co
Title:  Cells producing compositions with increased antibody dependent cytotoxic activity

U.S. Patent 8,067,232
Patent Owner: Kyowa Hakko Kirin Co.
Title: Antibody composition-producing cell with inactivated A-1, 6-fusocyltransferase

U.S. Patent 7,425,446
Patent Owner: Kyowa Hakko Kirin Co.
Title: Antibody composition-producing cell

U.S. Patent 7,332,289
Patent Owner: Chugai Pharmaceutical Co.
Title: Method of Purifying Protein

U.S. Patent 7,927,815
Patent Owner: Chugai Pharmaceutical Co.
Title: Protein Purification Method

U.S. Patent 6,870,034
Patent Owner: Genentech
Title:  Protein Purification

  • IPR2017-02029, filed by Boehringer Ingelheim
    • Filing date: August 31, 2017
    • Status: Institution decision pending as of August 31, 2017.

U.S. Patent 6,331,415
Patent Owner: Genentech
Title:  Methods of producing immunoglobulins, vectors and transformed host cells for use therein

U.S. Patent 7,807,799
Patent Owner:  Genentech
Title:  Reducing protein A leaching Affinity Chromatography

This page is maintained by Sarah Fink.

Download PDF